Commercialisation of biotechnology: Do dedicated public policies matter?

National governments are often confronted with the questions whether generic policy instruments are sufficient to support technology development and innovation and what justifies the introduction of instruments that focus on one specific technology. This article investigates the relationship between...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Science & public policy 2004-10, Vol.31 (5), p.371-383
Hauptverfasser:	Enzing, Christien, van der Giessen, Annelieke, Kern, Sander
Format:	Artikel
Sprache:	eng
Schlagworte:	Biotechnology Commercialization Cross-national analysis Europe European Union Industrial uses Innovation policy Knowledge Public policy Science Science policy Technological innovations
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	383
container_issue	5
container_start_page	371
container_title	Science & public policy
container_volume	31
creator	Enzing, Christien van der Giessen, Annelieke Kern, Sander
description	National governments are often confronted with the questions whether generic policy instruments are sufficient to support technology development and innovation and what justifies the introduction of instruments that focus on one specific technology. This article investigates the relationship between the commercial performance in biotechnology of 14 EU Member States and the presence of instruments that stimulate and support commercialisation of biotechnology in these countries. Our findings contradict the proposition that countries with dedicated biotech instruments show better commercialisation performance in biotechnology than countries without such instruments. Instead, success is more likely to be determined by the systemic character of public policies that address all elements of the innovation system, including instruments that stimulate the life sciences knowledge base and its commercialisation.
doi_str_mv	10.3152/147154304781779868
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_58862092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.3152/147154304781779868</oup_id><sourcerecordid>38021648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c298t-f3f3cf332d32f4a3533e00c2e9cdb52aafcb3d45d72086d2fad906f7b7784d773</originalsourceid><addsrcrecordid>eNqVkDtPwzAUhS0EEuXxB5gysQVsXzt2WBAqlCIqWEBFLJbjBxiSOsSJRP89rYpYGBDLPdLR993hIHRE8AkQTk8JE4QzwExIIkQpC7mFRusyX7fbaIQB0xwYFbtoL6U3jDGVjI_QdBybxnUm6Dok3Ye4yKLPqhB7Z14XsY4vy7PsMmbW2WB072zWDlUdTNbG1Q0uZY3ue9edH6Adr-vkDr9zHz1Orh7G03x2f30zvpjlhpayzz14MB6AWqCeaeAADmNDXWlsxanW3lRgGbeCYllY6rUtceFFJYRkVgjYR8ebv20XPwaXetWEZFxd64WLQ1JcyoLikv4JgsSUFEyuQLoBTRdT6pxXbRca3S0VwWq9rvq97krKN1Ic2n_xIfXu88fQ3bsqBAiupk_PanY7vyNzMVET-ALTu4kL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>38021648</pqid></control><display><type>article</type><title>Commercialisation of biotechnology: Do dedicated public policies matter?</title><source>PAIS Index</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Enzing, Christien ; van der Giessen, Annelieke ; Kern, Sander</creator><creatorcontrib>Enzing, Christien ; van der Giessen, Annelieke ; Kern, Sander ; Annelieke van der Giessen</creatorcontrib><description>National governments are often confronted with the questions whether generic policy instruments are sufficient to support technology development and innovation and what justifies the introduction of instruments that focus on one specific technology. This article investigates the relationship between the commercial performance in biotechnology of 14 EU Member States and the presence of instruments that stimulate and support commercialisation of biotechnology in these countries. Our findings contradict the proposition that countries with dedicated biotech instruments show better commercialisation performance in biotechnology than countries without such instruments. Instead, success is more likely to be determined by the systemic character of public policies that address all elements of the innovation system, including instruments that stimulate the life sciences knowledge base and its commercialisation.</description><identifier>ISSN: 0302-3427</identifier><identifier>EISSN: 1471-5430</identifier><identifier>DOI: 10.3152/147154304781779868</identifier><language>eng</language><publisher>Beech Tree Publishing</publisher><subject>Biotechnology ; Commercialization ; Cross-national analysis ; Europe ; European Union ; Industrial uses ; Innovation policy ; Knowledge ; Public policy ; Science ; Science policy ; Technological innovations</subject><ispartof>Science & public policy, 2004-10, Vol.31 (5), p.371-383</ispartof><rights>Beech Tree Publishing 2004 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c298t-f3f3cf332d32f4a3533e00c2e9cdb52aafcb3d45d72086d2fad906f7b7784d773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27865,27924,27925</link.rule.ids></links><search><creatorcontrib>Enzing, Christien</creatorcontrib><creatorcontrib>van der Giessen, Annelieke</creatorcontrib><creatorcontrib>Kern, Sander</creatorcontrib><creatorcontrib>Annelieke van der Giessen</creatorcontrib><title>Commercialisation of biotechnology: Do dedicated public policies matter?</title><title>Science & public policy</title><addtitle>sci public policy</addtitle><addtitle>sci public policy</addtitle><description>National governments are often confronted with the questions whether generic policy instruments are sufficient to support technology development and innovation and what justifies the introduction of instruments that focus on one specific technology. This article investigates the relationship between the commercial performance in biotechnology of 14 EU Member States and the presence of instruments that stimulate and support commercialisation of biotechnology in these countries. Our findings contradict the proposition that countries with dedicated biotech instruments show better commercialisation performance in biotechnology than countries without such instruments. Instead, success is more likely to be determined by the systemic character of public policies that address all elements of the innovation system, including instruments that stimulate the life sciences knowledge base and its commercialisation.</description><subject>Biotechnology</subject><subject>Commercialization</subject><subject>Cross-national analysis</subject><subject>Europe</subject><subject>European Union</subject><subject>Industrial uses</subject><subject>Innovation policy</subject><subject>Knowledge</subject><subject>Public policy</subject><subject>Science</subject><subject>Science policy</subject><subject>Technological innovations</subject><issn>0302-3427</issn><issn>1471-5430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>7TQ</sourceid><recordid>eNqVkDtPwzAUhS0EEuXxB5gysQVsXzt2WBAqlCIqWEBFLJbjBxiSOsSJRP89rYpYGBDLPdLR993hIHRE8AkQTk8JE4QzwExIIkQpC7mFRusyX7fbaIQB0xwYFbtoL6U3jDGVjI_QdBybxnUm6Dok3Ye4yKLPqhB7Z14XsY4vy7PsMmbW2WB072zWDlUdTNbG1Q0uZY3ue9edH6Adr-vkDr9zHz1Orh7G03x2f30zvpjlhpayzz14MB6AWqCeaeAADmNDXWlsxanW3lRgGbeCYllY6rUtceFFJYRkVgjYR8ebv20XPwaXetWEZFxd64WLQ1JcyoLikv4JgsSUFEyuQLoBTRdT6pxXbRca3S0VwWq9rvq97krKN1Ic2n_xIfXu88fQ3bsqBAiupk_PanY7vyNzMVET-ALTu4kL</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Enzing, Christien</creator><creator>van der Giessen, Annelieke</creator><creator>Kern, Sander</creator><general>Beech Tree Publishing</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8BJ</scope><scope>FQK</scope><scope>JBE</scope><scope>7TQ</scope><scope>DHY</scope><scope>DON</scope></search><sort><creationdate>20041001</creationdate><title>Commercialisation of biotechnology: Do dedicated public policies matter?</title><author>Enzing, Christien ; van der Giessen, Annelieke ; Kern, Sander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c298t-f3f3cf332d32f4a3533e00c2e9cdb52aafcb3d45d72086d2fad906f7b7784d773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biotechnology</topic><topic>Commercialization</topic><topic>Cross-national analysis</topic><topic>Europe</topic><topic>European Union</topic><topic>Industrial uses</topic><topic>Innovation policy</topic><topic>Knowledge</topic><topic>Public policy</topic><topic>Science</topic><topic>Science policy</topic><topic>Technological innovations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Enzing, Christien</creatorcontrib><creatorcontrib>van der Giessen, Annelieke</creatorcontrib><creatorcontrib>Kern, Sander</creatorcontrib><creatorcontrib>Annelieke van der Giessen</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>PAIS Index</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><jtitle>Science & public policy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Enzing, Christien</au><au>van der Giessen, Annelieke</au><au>Kern, Sander</au><aucorp>Annelieke van der Giessen</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Commercialisation of biotechnology: Do dedicated public policies matter?</atitle><jtitle>Science & public policy</jtitle><stitle>sci public policy</stitle><addtitle>sci public policy</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>31</volume><issue>5</issue><spage>371</spage><epage>383</epage><pages>371-383</pages><issn>0302-3427</issn><eissn>1471-5430</eissn><abstract>National governments are often confronted with the questions whether generic policy instruments are sufficient to support technology development and innovation and what justifies the introduction of instruments that focus on one specific technology. This article investigates the relationship between the commercial performance in biotechnology of 14 EU Member States and the presence of instruments that stimulate and support commercialisation of biotechnology in these countries. Our findings contradict the proposition that countries with dedicated biotech instruments show better commercialisation performance in biotechnology than countries without such instruments. Instead, success is more likely to be determined by the systemic character of public policies that address all elements of the innovation system, including instruments that stimulate the life sciences knowledge base and its commercialisation.</abstract><pub>Beech Tree Publishing</pub><doi>10.3152/147154304781779868</doi><tpages>13</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0302-3427
ispartof	Science & public policy, 2004-10, Vol.31 (5), p.371-383
issn	0302-3427 1471-5430
language	eng
recordid	cdi_proquest_miscellaneous_58862092
source	PAIS Index; Oxford University Press Journals All Titles (1996-Current)
subjects	Biotechnology Commercialization Cross-national analysis Europe European Union Industrial uses Innovation policy Knowledge Public policy Science Science policy Technological innovations
title	Commercialisation of biotechnology: Do dedicated public policies matter?
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A07%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Commercialisation%20of%20biotechnology:%20Do%20dedicated%20public%20policies%20matter?&rft.jtitle=Science%20&%20public%20policy&rft.au=Enzing,%20Christien&rft.aucorp=Annelieke%20van%20der%20Giessen&rft.date=2004-10-01&rft.volume=31&rft.issue=5&rft.spage=371&rft.epage=383&rft.pages=371-383&rft.issn=0302-3427&rft.eissn=1471-5430&rft_id=info:doi/10.3152/147154304781779868&rft_dat=%3Cproquest_cross%3E38021648%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=38021648&rft_id=info:pmid/&rft_oup_id=10.3152/147154304781779868&rfr_iscdi=true